UNH Q3 2026 Earnings Analysis
UnitedHealth Group reported Q3 2026 revenue of $113 billion with improved medical care ratio of 88.4%, raising full-year adjusted EPS guidance to at least $20.50 per share while advancing AI initiatives.
Key Metrics
Key Takeaways
- Medical care ratio improved to 88.4% from 89.9% with FY 2026 EPS guidance raised to at least $20.50
- UnitedHealthcare served 48.3 million people; Optum revenue reached $66.9B despite 10% Optum Health division decline
- Advancing AI initiatives to reduce prior authorizations by 30% by year-end and shorten appeal cycles by 26%
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the jargon from corporate earnings calls and turn them into something you can actually digest. I'm Alex.
And I'm Jordan. Today we're diving into UnitedHealth Group — ticker UNH — and their third quarter 2026 results, reported this week.
Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good to have that out front. So Alex, this was actually a pretty encouraging quarter for UnitedHealth after a rough stretch.
It really was. Let's start with the headline numbers. Revenue came in at $113 billion for the quarter. Adjusted earnings per share was $4.69 — compare that to just $2.92 a year ago. That's a massive jump.
And the metric everyone watches in this industry, the medical care ratio — basically what percentage of premium revenue goes out the door paying for medical claims — improved to 88.4%, down from 89.9% last year. Lower is better here, it means they're managing costs more effectively relative to what they're bringing in.
Right, and on the back of that they raised full-year guidance to at least $20.50 in adjusted EPS. CFO Wayne DeVeydt called that a "solid run rate to grow from," and interestingly, management said they think Wall Street's 2027 estimates might actually be too conservative.
That's a confident thing to say out loud on an earnings call. They're essentially telling analysts, "you might be underestimating us."
Let's talk segments for a second. UnitedHealthcare, the insurance arm, served 48.3 million people. Optum, their services arm, posted $66.9 billion in revenue — though Optum Health specifically saw a 10% revenue decline, which sounds alarming at first.
It does, but context matters. That's really a reflection of them pulling back from certain full-risk arrangements and refocusing on more disciplined, value-based care contracts rather than just chasing volume. Quality over quantity, essentially.
Now here's the thing that jumped out at me — commercial medical trend, meaning cost growth in their employer-sponsored insurance business, is running above 11%. That's way above historical norms.
And they were pretty pointed about why. Two big drivers: high-cost specialty drugs, which is an industry-wide story at this point, and something more unique to UnitedHealth's commentary — arbitration awards tied to the No Surprises Act.
Explain that one, because it's a little wonky.
Sure. The No Surprises Act was designed to protect patients from surprise out-of-network bills. But there's a dispute resolution process built into it, and UnitedHealth is saying certain provider groups are gaming that process — arbitration awards in some regions are approaching 6% of total medical spend. Management was blunt, calling it "abuse" of the system, and said it's translating to billions in excess costs.
So this isn't just "healthcare costs are high," it's "there's a specific regulatory mechanism being exploited."
Exactly, and they're actively lobbying regulators on it. Worth watching into 2027.
Let's shift to the strategic story, because this is where it gets interesting. CEO Steve Hemsley leaned hard into AI throughout the call. They've rolled out AI-enabled chart summarization to over 40% of employed clinicians, cutting chart review time by a third. AI-assisted appeals processing cut cycle times by 26%.
And the big one for anyone who's ever dealt with insurance red tape — they're on track to cut prior authorization volumes by 30% by year-end, including a two-thirds reduction for patients under 18. That's a real, tangible change for members and doctors dealing with administrative friction.
It's smart positioning too. UnitedHealth has taken public heat over prior authorization practices, so leading with "we're cutting this dramatically" is as much a PR move as an efficiency one.
Both things can be true. Now, on the Q&A side, a few things stood out to me. On Medicaid, executives said margins are improving faster than expected — now expected to be "moderately better than negative 1%" for the year, with a goal of getting back to target margins by 2028.
And on Medicare Advantage, they said they expect to land near the top of their 2%-4% margin range for the year, which is a nice recovery story after some benefit redesign pain in 2026.
The commercial business was the one area where they tempered expectations a bit. Executives admitted that elevated trend pressure is going to "stretch out" their timeline for getting back to historical margins in that segment.
Capital allocation was solid too — $5 billion in buybacks through Q3, and dividends are expected to top $8 billion by year-end. Debt-to-cap ratio improving toward that 40% target.
So what does this mean for investors going forward? The turnaround story looks like it's gaining real traction — better cost ratios, raised guidance, management expressing more confidence than we've heard from them in a while about 2027's 13%-to-16% long-term growth target.
But there are real headwinds still in play — persistent commercial cost trends, the No Surprises Act dispute issue, and Optum Health's revenue still working through that strategic repositioning.
Before we wrap up, our standard closer: everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Management promised more detailed 2027 guidance before year-end, so we'll be back to unpack that when it lands.
Until then, this has been Beta Finch — thanks for listening, and we'll catch you next time.
Take care, everyone.